However, in stage IV, the prognostic value of CDX2 expression was independent of chemotherapy (Fig. S5B), and CDX2 was not found to have a predictive value for treatment response in this cancer stage, as the rate of 5‐year OS was similar for patients with CDX2‐negative and CDX2‐positive tumors when comparing those who received chemotherapy to patients who did not receive chemotherapy (Fig. 3B; formal test for interaction: P = 0.31). Here, CDX2 is linked to cancer.